Preclinical CRO Market Size, Share & Trends Analysis Report By Service (Toxicology Testing, Bioanalysis & DMPK Studies), By End Use (Biopharmaceutical Companies, Government & Academic Institutes), And Segment Forecasts, 2022 - 2030
This report can be delivered to the clients within 72 Business Hours
Preclinical CRO Market Growth & Trends
The global preclinical CRO market size is expected to reach USD 9.67 billion by 2030, expanding at a CAGR of 7.9%, according to a new report by Grand View Research, Inc. The market is expected to show lucrative growth due to increasing R&D expenditure and rising outsourcing trends. The increasing volume of new drugs entering the preclinical phase is also anticipated to boost the market during the forecast period. However, the COVID-19 pandemic had temporarily affected the market owing to the shutdown of research sites due to the implementation of national lockdowns.
The market is undergoing a series of mergers and acquisitions, resulting in improvement in full-service capabilities and the international reach of larger companies. For instance, in 2019, WuXi AppTec acquired Pharmapace. On the other hand, mid-sized and smaller contract research organizations are focusing on niche sectors and are providing a personalized approach to their sponsors. Various companies are focusing on research and development of new drugs and therefore are outsourcing these activities to launch efficient CRO services in the market. This, in turn, provides a positive atmosphere for joint ventures among market participants owing to the preference of sponsors to maximize their benefits.
The COVID-19 pandemic is ever increasing since the disease was first identified in China in December 2019. Until March 9, 2022, more than 4500 million cases of COVID-19 were reported globally; this pandemic has fast-tracked the development of vaccines and drug testing. There are currently over 195 COVID-19 vaccine candidates in preclinical studies.
Preclinical CRO Market Report Highlights
Preclinical CRO Market Growth & Trends
The global preclinical CRO market size is expected to reach USD 9.67 billion by 2030, expanding at a CAGR of 7.9%, according to a new report by Grand View Research, Inc. The market is expected to show lucrative growth due to increasing R&D expenditure and rising outsourcing trends. The increasing volume of new drugs entering the preclinical phase is also anticipated to boost the market during the forecast period. However, the COVID-19 pandemic had temporarily affected the market owing to the shutdown of research sites due to the implementation of national lockdowns.
The market is undergoing a series of mergers and acquisitions, resulting in improvement in full-service capabilities and the international reach of larger companies. For instance, in 2019, WuXi AppTec acquired Pharmapace. On the other hand, mid-sized and smaller contract research organizations are focusing on niche sectors and are providing a personalized approach to their sponsors. Various companies are focusing on research and development of new drugs and therefore are outsourcing these activities to launch efficient CRO services in the market. This, in turn, provides a positive atmosphere for joint ventures among market participants owing to the preference of sponsors to maximize their benefits.
The COVID-19 pandemic is ever increasing since the disease was first identified in China in December 2019. Until March 9, 2022, more than 4500 million cases of COVID-19 were reported globally; this pandemic has fast-tracked the development of vaccines and drug testing. There are currently over 195 COVID-19 vaccine candidates in preclinical studies.
Preclinical CRO Market Report Highlights
- The toxicology testing segment accounted for the largest share of more than 25.48% in 2021 due to its significance in Investigational New Drug (IND)-enabling studies
- The Patient Derived Organoid (PDO) Model segment held the largest share of 80.47% in 2021, owing to the high accuracy obtained by this model
- The government and academic institutes segment is anticipated to witness the fastest CAGR of 8.2% during the forecast period. This growth is credited to the rising government initiatives in the healthcare sector, especially in developing economies
- North America held the highest revenue share of the global market in 2021. Huge investments in healthcare R&D, coupled with well-developed healthcare infrastructure in the U.S., contributed to the market growth in North America. Asia Pacific is projected to expand with the fastest CAGR of 10.9% during the forecast period
CHAPTER 1 METHODOLOGY AND SCOPE
1.1 Market Segmentation & Scope
1.1.1 Regional Scope
1.1.2 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Gvr’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.2 Volume Price Analysis (Model 2)
1.7 List of Secondary Sources
1.8 List of Primary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective -
1.10.2 Objective -
1.10.3 Objective -
1.10.4 Objective -
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Outlook
CHAPTER 3 PRECLINICAL CRO MARKET: VARIABLES, TRENDS, & SCOPE
3.1 Segment Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Market Dynamics
3.3.1 Market Driver Analysis
3.4 Rising R&D offshoring
3.4.1.1 Rising outsourcing trend
3.4.1.2 Life sciences companies focusing on their core competencieS
3.4.2 Market Restraint Analysis
3.4.2.1 Monitoring issues and lack of standardization
3.5 Preclinical CRO Market Analysis Tools
3.5.1 Porter’s Five Forces Analysis
3.5.2 Industry Analysis Porter’s
3.5.2.1 Competitor rivalry (High)
3.5.2.2 Bargaining power of buyers(high)
3.5.2.3 Bargaining power of suppliers(Low)
3.5.2.4 Threat of substitutes (low)
3.5.2.5 Threat of new entrants (Low)
3.5.3 PESTEL Analysis
3.5.3.1 PESTLE Analysis
3.5.3.1.1 Political And LegaL
3.5.3.1.1.1 Strengths
3.5.3.1.1.2 Weaknesses
3.5.3.1.1.3 Opportunities
3.5.3.1.1.4 Threats
3.5.3.1.2 Economic
3.5.3.1.2.1 Strengths
3.5.3.1.2.2 Weaknesses
3.5.3.1.2.3 Opportunities
3.5.3.1.2.4 Threats
3.5.3.1.3 Social and Environmental
3.5.3.1.3.1 Strengths
3.5.3.1.3.2 Weaknesses
3.5.3.1.3.3 Opportunities
3.5.3.1.3.4 Threats
3.6 COVID-19 Impact Analysis
CHAPTER 4 PRECLINICAL CRO MARKET: SERVICE SEGMENT ANALYSIS
4.1 Definitions & Scope
4.2 Preclinical CRO: Market Service Share Analysis, 2021 & 2030
4.3 Bioanalysis and DMPK Studies
4.3.1 Bioanalysis and DMPK studies market, 2018 - 2030 (USD Million)
4.3.2 In-vitro ADME
4.3.2.1 In-vitro Adme Market, 2018 - 2030 (USD Million)
4.3.3 In-Vivo Pk
4.3.3.1 In-Vivo Pk Market, 2018 - 2030 (USD Million)
4.4 Toxicology Testing
4.4.1 Toxicology Testing Market, 2018 - 2030 (USD Million)
4.4.2 Glp
4.4.2.1 Glp Market, 2018 - 2030 (USD Million)
4.4.3 Non-Glp
4.4.3.1 Non-Glp Market, 2018 - 2030 (USD Million)
4.5 Compound Management
4.5.1 Compound Management Companies market, 2018 - 2030 (USD Million)
4.5.2 Process R&D
4.5.2.1 Process r&D Market, 2018 - 2030 (USD Million)
4.5.3 Custom Synthesis
4.5.3.1 Custom Synthesis Market, 2018 - 2030 (USD Million)
4.5.4 Others
4.5.4.1 Others Market, 2018 - 2030 (USD Million)
4.6 Chemistry
4.6.1 Chemistry Testing Market, 2018 - 2030 (USD Million)
4.6.2 Medicinal Chemistry
4.6.2.1 Medicinal Chemistry Market, 2018 - 2030 (USD Million)
4.6.3 Computation Chemistry
4.6.3.1 Computation Chemistry Market, 2018 - 2030 (USD Million)
4.7 Safety Pharmacology
4.7.1 Safety Pharmacology market, 2018 - 2030 (USD Million)
4.8 Others
4.8.1 Others market, 2018 - 2030 (USD Million)
CHAPTER 5 PRECLINICAL CRO MARKET: MODEL TYPE SEGMENT ANALYSIS
5.1 Definition & Scope
5.2 Preclinical CRO: Market Model Type Share Analysis, 2021 & 2030
5.3 Patient Derived Organoid (PDOs) Models
5.3.1 Patient Derived Organoid (PDOs) Models market, 2018 - 2030 (USD Million)
5.4 Patient Derived Xenograft (PDX) Models
5.4.1 Patient Derived Xenograft (PDX) Models market, 2018 - 2030 (USD Million)
CHAPTER 6 PRECLINICAL CRO MARKET: END-USE SEGMENT ANALYSIS
6.1 Definitions & Scope
6.2 Preclinical CRO: Market End-use Share Analysis, 2021 & 2030
6.3 Biopharmaceutical Companies
6.3.1 Biopharmaceutical companies market, 2018 - 2030 (USD Million)
6.4 Government and Academic Institutes
6.4.1 Government and Academic Institutes market, 2018 - 2030 (USD Million)
6.5 Medical Device Companies
6.5.1 Medical Device Companies market, 2018 - 2030 (USD Million)
CHAPTER 7 PRECLINICAL CRO MARKET: REGIONAL ANALYSIS
7.1 Preclinical CRO: Market Share Analysis, 2021 & 2030
7.2 North America
7.2.1 North America Preclinical CRO market, 2018 - 2030 (USD Million)
7.2.2 U.S.
7.2.2.1 U.S. Preclinical CRO market, 2018 - 2030 (USD Million)
7.2.3 Canada
7.2.3.1 Canada preclinical CRO market, 2018 - 2030 (USD Million)
7.3 Europe
7.3.1 Europe preclinical CRO market, 2018 - 2030 (USD Million)
7.3.2 UK
7.3.2.1 UK preclinical CRO market, 2018 - 2030 (USD Million)
7.3.3 Germany
7.3.3.1 Germany Preclinical CRO market, 2018 - 2030 (USD Million)
7.3.4 France
7.3.5 France preclinical CRO market, 2018 - 2030 (USD Million)
7.3.6 Italy
7.3.7 Italy preclinical CRO market, 2018 - 2030 (USD Million)
7.3.8 Spain
7.3.9 Spain preclinical CRO market, 2018 - 2030 (USD Million)
7.4 Asia Pacific
7.4.1 Asia Pacific Preclinical CRO Market, 2018 - 2030 (USD Million)
7.4.2 Japan
7.4.2.1 Japan Preclinical CRO Market, 2018 - 2030 (USD Million)
7.4.3 China
7.4.3.1 China Preclinical CRO Market, 2018 - 2030 (USD Million)
7.4.4 India
7.4.4.1 India Preclinical CRO Market, 2018 - 2030 (USD Million)
7.4.5 Australia
7.4.5.1 Australia Preclinical CRO Market, 2018 - 2030 (USD Million)
7.4.6 South Korea
7.4.6.1 South Korea Preclinical CRO Market, 2018 - 2030 (USD Million)
7.5 Latin America
7.5.1 Latin America Preclinical CRO Market, 2018 - 2030 (USD Million)
7.5.2 Brazil
7.5.2.1 Brazil Preclinical CRO Market, 2018 - 2030 (USD Million)
7.5.3 Mexico
7.5.4 Mexico Preclinical CRO Market, 2018 - 2030 (USD Million)
7.5.5 Argentina
7.5.5.1 Argentina Preclinical CRO Market, 2018 - 2030 (USD Million)
7.6 MEA
7.6.1 MEA Preclinical CRO Market, 2018 - 2030 (USD Million)
7.6.2 South Africa
7.6.2.1 South Africa Preclinical CRO market, 2018 - 2030 (USD Million)
7.6.3 Saudi Arabia
7.6.3.1 Saudi Arabia Preclinical CRO market, 2018 - 2030 (USD Million)
CHAPTER 8 COMPANY PROFILES
8.1 Company Profiles
8.1.1 WuXi AppTec, Inc. (WAI)
8.1.1.1 Company overview
8.1.1.2 Financial performance
8.1.1.3 Service benchmarking
8.1.1.4 Strategic initiatives
8.1.2 LABCORP
8.1.2.1 Company overview
8.1.2.2 Financial performance
8.1.2.3 Service benchmarking
8.1.2.4 Strategic initiatives
8.1.3 Eurofins scientific se
8.1.3.1 Company overview
8.1.3.2 Financial performance
8.1.3.3 Service benchmarking
8.1.3.4 Strategic initiatives
8.1.4 Medpace holdings inc.
8.1.4.1 Company overview
8.1.4.2 Financial performance
8.1.4.3 Service benchmarking
8.1.5 Charles River Laboratories International, Inc.
8.1.5.1 Company overview
8.1.5.2 Financial performance
8.1.5.3 Service benchmarking
8.1.5.4 Strategic initiatives
8.1.6 Intertek group plc (igp)
8.1.6.1 Company overview
8.1.6.2 Financial performance
8.1.6.3 Service benchmarking
8.1.6.4 Strategic initiatives
8.1.7 SGA SA
8.1.7.1 Company overview
8.1.7.2 Financial performance
8.1.7.3 Service benchmarking
8.1.7.4 Strategic initiatives
8.1.8 PPD (THERMO FISHER SCIENTIFIC, INC.)
8.1.8.1 Company overview
8.1.8.2 Financial performance
8.1.8.3 Service benchmarking
8.1.8.4 Strategic initiatives
8.1.9 PRA Health Sciences, INC. (ICON plc)
8.1.9.1 Company overview
8.1.9.2 Financial performance
8.1.9.3 Service benchmarking
8.1.9.4 Strategic Initiatives
8.1.10 CROwn bioscience
8.1.10.1 Company overview
8.1.10.2 Financial performance
8.1.10.3 Service benchmarking
8.1.10.4 Strategic initiatives
1.1 Market Segmentation & Scope
1.1.1 Regional Scope
1.1.2 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Gvr’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis (Model 1)
1.6.2 Volume Price Analysis (Model 2)
1.7 List of Secondary Sources
1.8 List of Primary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective -
1.10.2 Objective -
1.10.3 Objective -
1.10.4 Objective -
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Outlook
CHAPTER 3 PRECLINICAL CRO MARKET: VARIABLES, TRENDS, & SCOPE
3.1 Segment Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Market Dynamics
3.3.1 Market Driver Analysis
3.4 Rising R&D offshoring
3.4.1.1 Rising outsourcing trend
3.4.1.2 Life sciences companies focusing on their core competencieS
3.4.2 Market Restraint Analysis
3.4.2.1 Monitoring issues and lack of standardization
3.5 Preclinical CRO Market Analysis Tools
3.5.1 Porter’s Five Forces Analysis
3.5.2 Industry Analysis Porter’s
3.5.2.1 Competitor rivalry (High)
3.5.2.2 Bargaining power of buyers(high)
3.5.2.3 Bargaining power of suppliers(Low)
3.5.2.4 Threat of substitutes (low)
3.5.2.5 Threat of new entrants (Low)
3.5.3 PESTEL Analysis
3.5.3.1 PESTLE Analysis
3.5.3.1.1 Political And LegaL
3.5.3.1.1.1 Strengths
3.5.3.1.1.2 Weaknesses
3.5.3.1.1.3 Opportunities
3.5.3.1.1.4 Threats
3.5.3.1.2 Economic
3.5.3.1.2.1 Strengths
3.5.3.1.2.2 Weaknesses
3.5.3.1.2.3 Opportunities
3.5.3.1.2.4 Threats
3.5.3.1.3 Social and Environmental
3.5.3.1.3.1 Strengths
3.5.3.1.3.2 Weaknesses
3.5.3.1.3.3 Opportunities
3.5.3.1.3.4 Threats
3.6 COVID-19 Impact Analysis
CHAPTER 4 PRECLINICAL CRO MARKET: SERVICE SEGMENT ANALYSIS
4.1 Definitions & Scope
4.2 Preclinical CRO: Market Service Share Analysis, 2021 & 2030
4.3 Bioanalysis and DMPK Studies
4.3.1 Bioanalysis and DMPK studies market, 2018 - 2030 (USD Million)
4.3.2 In-vitro ADME
4.3.2.1 In-vitro Adme Market, 2018 - 2030 (USD Million)
4.3.3 In-Vivo Pk
4.3.3.1 In-Vivo Pk Market, 2018 - 2030 (USD Million)
4.4 Toxicology Testing
4.4.1 Toxicology Testing Market, 2018 - 2030 (USD Million)
4.4.2 Glp
4.4.2.1 Glp Market, 2018 - 2030 (USD Million)
4.4.3 Non-Glp
4.4.3.1 Non-Glp Market, 2018 - 2030 (USD Million)
4.5 Compound Management
4.5.1 Compound Management Companies market, 2018 - 2030 (USD Million)
4.5.2 Process R&D
4.5.2.1 Process r&D Market, 2018 - 2030 (USD Million)
4.5.3 Custom Synthesis
4.5.3.1 Custom Synthesis Market, 2018 - 2030 (USD Million)
4.5.4 Others
4.5.4.1 Others Market, 2018 - 2030 (USD Million)
4.6 Chemistry
4.6.1 Chemistry Testing Market, 2018 - 2030 (USD Million)
4.6.2 Medicinal Chemistry
4.6.2.1 Medicinal Chemistry Market, 2018 - 2030 (USD Million)
4.6.3 Computation Chemistry
4.6.3.1 Computation Chemistry Market, 2018 - 2030 (USD Million)
4.7 Safety Pharmacology
4.7.1 Safety Pharmacology market, 2018 - 2030 (USD Million)
4.8 Others
4.8.1 Others market, 2018 - 2030 (USD Million)
CHAPTER 5 PRECLINICAL CRO MARKET: MODEL TYPE SEGMENT ANALYSIS
5.1 Definition & Scope
5.2 Preclinical CRO: Market Model Type Share Analysis, 2021 & 2030
5.3 Patient Derived Organoid (PDOs) Models
5.3.1 Patient Derived Organoid (PDOs) Models market, 2018 - 2030 (USD Million)
5.4 Patient Derived Xenograft (PDX) Models
5.4.1 Patient Derived Xenograft (PDX) Models market, 2018 - 2030 (USD Million)
CHAPTER 6 PRECLINICAL CRO MARKET: END-USE SEGMENT ANALYSIS
6.1 Definitions & Scope
6.2 Preclinical CRO: Market End-use Share Analysis, 2021 & 2030
6.3 Biopharmaceutical Companies
6.3.1 Biopharmaceutical companies market, 2018 - 2030 (USD Million)
6.4 Government and Academic Institutes
6.4.1 Government and Academic Institutes market, 2018 - 2030 (USD Million)
6.5 Medical Device Companies
6.5.1 Medical Device Companies market, 2018 - 2030 (USD Million)
CHAPTER 7 PRECLINICAL CRO MARKET: REGIONAL ANALYSIS
7.1 Preclinical CRO: Market Share Analysis, 2021 & 2030
7.2 North America
7.2.1 North America Preclinical CRO market, 2018 - 2030 (USD Million)
7.2.2 U.S.
7.2.2.1 U.S. Preclinical CRO market, 2018 - 2030 (USD Million)
7.2.3 Canada
7.2.3.1 Canada preclinical CRO market, 2018 - 2030 (USD Million)
7.3 Europe
7.3.1 Europe preclinical CRO market, 2018 - 2030 (USD Million)
7.3.2 UK
7.3.2.1 UK preclinical CRO market, 2018 - 2030 (USD Million)
7.3.3 Germany
7.3.3.1 Germany Preclinical CRO market, 2018 - 2030 (USD Million)
7.3.4 France
7.3.5 France preclinical CRO market, 2018 - 2030 (USD Million)
7.3.6 Italy
7.3.7 Italy preclinical CRO market, 2018 - 2030 (USD Million)
7.3.8 Spain
7.3.9 Spain preclinical CRO market, 2018 - 2030 (USD Million)
7.4 Asia Pacific
7.4.1 Asia Pacific Preclinical CRO Market, 2018 - 2030 (USD Million)
7.4.2 Japan
7.4.2.1 Japan Preclinical CRO Market, 2018 - 2030 (USD Million)
7.4.3 China
7.4.3.1 China Preclinical CRO Market, 2018 - 2030 (USD Million)
7.4.4 India
7.4.4.1 India Preclinical CRO Market, 2018 - 2030 (USD Million)
7.4.5 Australia
7.4.5.1 Australia Preclinical CRO Market, 2018 - 2030 (USD Million)
7.4.6 South Korea
7.4.6.1 South Korea Preclinical CRO Market, 2018 - 2030 (USD Million)
7.5 Latin America
7.5.1 Latin America Preclinical CRO Market, 2018 - 2030 (USD Million)
7.5.2 Brazil
7.5.2.1 Brazil Preclinical CRO Market, 2018 - 2030 (USD Million)
7.5.3 Mexico
7.5.4 Mexico Preclinical CRO Market, 2018 - 2030 (USD Million)
7.5.5 Argentina
7.5.5.1 Argentina Preclinical CRO Market, 2018 - 2030 (USD Million)
7.6 MEA
7.6.1 MEA Preclinical CRO Market, 2018 - 2030 (USD Million)
7.6.2 South Africa
7.6.2.1 South Africa Preclinical CRO market, 2018 - 2030 (USD Million)
7.6.3 Saudi Arabia
7.6.3.1 Saudi Arabia Preclinical CRO market, 2018 - 2030 (USD Million)
CHAPTER 8 COMPANY PROFILES
8.1 Company Profiles
8.1.1 WuXi AppTec, Inc. (WAI)
8.1.1.1 Company overview
8.1.1.2 Financial performance
8.1.1.3 Service benchmarking
8.1.1.4 Strategic initiatives
8.1.2 LABCORP
8.1.2.1 Company overview
8.1.2.2 Financial performance
8.1.2.3 Service benchmarking
8.1.2.4 Strategic initiatives
8.1.3 Eurofins scientific se
8.1.3.1 Company overview
8.1.3.2 Financial performance
8.1.3.3 Service benchmarking
8.1.3.4 Strategic initiatives
8.1.4 Medpace holdings inc.
8.1.4.1 Company overview
8.1.4.2 Financial performance
8.1.4.3 Service benchmarking
8.1.5 Charles River Laboratories International, Inc.
8.1.5.1 Company overview
8.1.5.2 Financial performance
8.1.5.3 Service benchmarking
8.1.5.4 Strategic initiatives
8.1.6 Intertek group plc (igp)
8.1.6.1 Company overview
8.1.6.2 Financial performance
8.1.6.3 Service benchmarking
8.1.6.4 Strategic initiatives
8.1.7 SGA SA
8.1.7.1 Company overview
8.1.7.2 Financial performance
8.1.7.3 Service benchmarking
8.1.7.4 Strategic initiatives
8.1.8 PPD (THERMO FISHER SCIENTIFIC, INC.)
8.1.8.1 Company overview
8.1.8.2 Financial performance
8.1.8.3 Service benchmarking
8.1.8.4 Strategic initiatives
8.1.9 PRA Health Sciences, INC. (ICON plc)
8.1.9.1 Company overview
8.1.9.2 Financial performance
8.1.9.3 Service benchmarking
8.1.9.4 Strategic Initiatives
8.1.10 CROwn bioscience
8.1.10.1 Company overview
8.1.10.2 Financial performance
8.1.10.3 Service benchmarking
8.1.10.4 Strategic initiatives
LIST OF TABLES
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 1 List of secondary sources
Table 2 List of abbreviations
LIST OF FIGURES
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Market formulation & validation
Fig. 6 Commodity flow analysis
Fig. 7 Volume price analysis
Fig. 8 Preclinical CRO market snapshot (2021) (USD Million)
Fig. 9 Preclinical CRO market segmentation
Fig. 10 Penetration & growth prospect mapping
Fig. 11 Market driver relevance analysis (Current & future impact)
Fig. 12 Market restraint relevance analysis (Current & future impact)
Fig. 13 Porter’s five forces analysis
Fig. 14 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 15 Preclinical CRO market service outlook: Segment dashboard
Fig. 16 Preclinical CRO market: Service movement analysis
Fig. 17 Bioanalysis and DMPK studies market, 2018 - 2030 (USD Million)
Fig. 18 In-vitro ADME market, 2018 - 2030 (USD Million)
Fig. 19 In-vivo PK market, 2018 - 2030 (USD Million)
Fig. 20 Toxicology testing market, 2018 - 2030 (USD Million)
Fig. 21 GLP market, 2018 - 2030 (USD Million)
Fig. 22 Non-GLP market, 2018 - 2030 (USD Million)
Fig. 23 Non-mammalian source market, 2018 - 2030 (USD Million)
Fig. 24 Process R&D market, 2018 - 2030 (USD Million)
Fig. 25 Custom synthesis market, 2018 - 2030 (USD Million)
Fig. 26 Others market, 2018 - 2030 (USD Million)
Fig. 27 Chemistry market, 2018 - 2030 (USD Million)
Fig. 28 Medicinal chemistry market, 2018 - 2030 (USD Million)
Fig. 29 Computation chemistry market, 2018 - 2030 (USD Million)
Fig. 30 Safety pharmacology market, 2018 - 2030 (USD Million)
Fig. 31 Others market, 2018 - 2030 (USD Million)
Fig. 32 Preclinical CRO market model type outlook: Segment dashboard
Fig. 33 Preclinical CRO market: Model type movement analysis
Fig. 34 Patient derived organoid (PDO) models market, 2018 - 2030 (USD Million)
Fig. 35 Patient derived xenograft (PDX) models market, 2018 - 2030 (USD Million)
Fig. 36 Preclinical CRO market end-use outlook: Segment dashboard
Fig. 37 Preclinical CRO market: End-use movement analysis
Fig. 38 Biopharmaceutical companies market, 2018 - 2030 (USD Million)
Fig. 39 Government and academic institutes market, 2018 - 2030 (USD Million)
Fig. 40 Medical device companies market, 2018 - 2030 (USD Million)
Fig. 41 Regional market: Key takeaways
Fig. 42 Regional outlook, 2021 & 2030
Fig. 43 North America market, 2018 - 2030 (USD Million)
Fig. 44 U.S. market, 2018 - 2030 (USD Million)
Fig. 45 Canada market, 2018 - 2030 (USD Million)
Fig. 46 Europe market, 2018 - 2030 (USD Million)
Fig. 47 UK market, 2018 - 2030 (USD Million)
Fig. 48 Germany market, 2018 - 2030 (USD Million)
Fig. 49 France market, 2018 - 2030 (USD Million )
Fig. 50 Italy market, 2018 - 2030 (USD Million )
Fig. 51 Spain market, 2018 - 2030 (USD Million )
Fig. 52 Asia Pacific market, 2018 - 2030 (USD Million)
Fig. 53 Japan market, 2018 - 2030 (USD Million)
Fig. 54 China market, 2018 - 2030 (USD Million)
Fig. 55 India market, 2018 - 2030 (USD Million )
Fig. 56 Australia market, 2018 - 2030 (USD Million )
Fig. 57 South Korea market, 2018 - 2030 (USD Million)
Fig. 58 Latin America market, 2018 - 2030 (USD Million)
Fig. 59 Brazil market, 2018 - 2030 (USD Million)
Fig. 60 Mexico market, 2018 - 2030 (USD Million)
Fig. 61 Argentina market, 2018 - 2030 (USD Million)
Fig. 62 MEA market, 2018 - 2030 (USD Million)
Fig. 63 South Africa market, 2018 - 2030 (USD Million)
Fig. 64 Saudi Arabia market, 2018 - 2030 (USD Million)
Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Market formulation & validation
Fig. 6 Commodity flow analysis
Fig. 7 Volume price analysis
Fig. 8 Preclinical CRO market snapshot (2021) (USD Million)
Fig. 9 Preclinical CRO market segmentation
Fig. 10 Penetration & growth prospect mapping
Fig. 11 Market driver relevance analysis (Current & future impact)
Fig. 12 Market restraint relevance analysis (Current & future impact)
Fig. 13 Porter’s five forces analysis
Fig. 14 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 15 Preclinical CRO market service outlook: Segment dashboard
Fig. 16 Preclinical CRO market: Service movement analysis
Fig. 17 Bioanalysis and DMPK studies market, 2018 - 2030 (USD Million)
Fig. 18 In-vitro ADME market, 2018 - 2030 (USD Million)
Fig. 19 In-vivo PK market, 2018 - 2030 (USD Million)
Fig. 20 Toxicology testing market, 2018 - 2030 (USD Million)
Fig. 21 GLP market, 2018 - 2030 (USD Million)
Fig. 22 Non-GLP market, 2018 - 2030 (USD Million)
Fig. 23 Non-mammalian source market, 2018 - 2030 (USD Million)
Fig. 24 Process R&D market, 2018 - 2030 (USD Million)
Fig. 25 Custom synthesis market, 2018 - 2030 (USD Million)
Fig. 26 Others market, 2018 - 2030 (USD Million)
Fig. 27 Chemistry market, 2018 - 2030 (USD Million)
Fig. 28 Medicinal chemistry market, 2018 - 2030 (USD Million)
Fig. 29 Computation chemistry market, 2018 - 2030 (USD Million)
Fig. 30 Safety pharmacology market, 2018 - 2030 (USD Million)
Fig. 31 Others market, 2018 - 2030 (USD Million)
Fig. 32 Preclinical CRO market model type outlook: Segment dashboard
Fig. 33 Preclinical CRO market: Model type movement analysis
Fig. 34 Patient derived organoid (PDO) models market, 2018 - 2030 (USD Million)
Fig. 35 Patient derived xenograft (PDX) models market, 2018 - 2030 (USD Million)
Fig. 36 Preclinical CRO market end-use outlook: Segment dashboard
Fig. 37 Preclinical CRO market: End-use movement analysis
Fig. 38 Biopharmaceutical companies market, 2018 - 2030 (USD Million)
Fig. 39 Government and academic institutes market, 2018 - 2030 (USD Million)
Fig. 40 Medical device companies market, 2018 - 2030 (USD Million)
Fig. 41 Regional market: Key takeaways
Fig. 42 Regional outlook, 2021 & 2030
Fig. 43 North America market, 2018 - 2030 (USD Million)
Fig. 44 U.S. market, 2018 - 2030 (USD Million)
Fig. 45 Canada market, 2018 - 2030 (USD Million)
Fig. 46 Europe market, 2018 - 2030 (USD Million)
Fig. 47 UK market, 2018 - 2030 (USD Million)
Fig. 48 Germany market, 2018 - 2030 (USD Million)
Fig. 49 France market, 2018 - 2030 (USD Million )
Fig. 50 Italy market, 2018 - 2030 (USD Million )
Fig. 51 Spain market, 2018 - 2030 (USD Million )
Fig. 52 Asia Pacific market, 2018 - 2030 (USD Million)
Fig. 53 Japan market, 2018 - 2030 (USD Million)
Fig. 54 China market, 2018 - 2030 (USD Million)
Fig. 55 India market, 2018 - 2030 (USD Million )
Fig. 56 Australia market, 2018 - 2030 (USD Million )
Fig. 57 South Korea market, 2018 - 2030 (USD Million)
Fig. 58 Latin America market, 2018 - 2030 (USD Million)
Fig. 59 Brazil market, 2018 - 2030 (USD Million)
Fig. 60 Mexico market, 2018 - 2030 (USD Million)
Fig. 61 Argentina market, 2018 - 2030 (USD Million)
Fig. 62 MEA market, 2018 - 2030 (USD Million)
Fig. 63 South Africa market, 2018 - 2030 (USD Million)
Fig. 64 Saudi Arabia market, 2018 - 2030 (USD Million)
